Work

Introducing the Investigator Global Assessment of Hidradenitis Suppurativa (I-GLASS) instrument

Year: 2026

Type: article

Abstract: To date, the primary endpoint of hidradenitis suppurativa (HS) clinical trials is typically a focused lesion count, which has been shown to be error prone and which may not comprehensively measure the inflammatory burden. Unlike lesions of other inflammatory skin diseases such as atopic dermatitis, vitiligo and alopecia areata, HS lesions exhibit substantial morphological heterogeneity. Accordingly, the Investigator Global Assessment of Hidradenitis Suppurativa (I-GLASS) instrument was developed.

Source: British Journal of Dermatology

DOI: 10.1093/bjd/ljag083

Authors: John R Ingram, Amit Garg

Institutions: Cardiff University, Northwell Health

Language: English

Topic: Hidradenitis Suppurativa and Treatments

Subfield: Dermatology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: hybrid

Estimated APC paid: $4,920